Search PubMed⌕ Search

Biomedical subjects

Robert Lynch

Publications and source records attributed to Robert Lynch.

4 recordsLinked to original sources

Determinants of exposure to volatile organic compounds in four Oklahoma cities.

To begin to develop generalized models for estimating personal exposure to ambient air pollutants within diverse populations, the design of the Oklahoma Urban Air Toxics Study incorporated eight dichotomous macroenvironmental and household factors that were hypothesized to be potential determinants of exposure. Personal, indoor, and outdoor samples of volatile organic compounds (VOCs) were collected over 24-h monitoring periods in 42 households, together with activity diaries and data on the participants' residences. The distributions of the VOC concentrations were moderately to highly left-censored, and were mostly bimodal. The ATSDR minimal risk level (MRL) was exceeded in a small number of the samples. Personal and indoor concentrations tended to be higher than outdoor concentrations, indicating that indoor exposures were dominated by indoor sources. However, indoor concentrations were not correlated with the permeability of the residence, suggesting that the observed indoor concentrations reflected mostly localized, short-term emissions. The influence of the eight dichotomous factors and of the presence of an attached garage was evaluated using the Wilcoxon rank-sum test and by comparison of "excursion fractions", that is, the fractions of each distributions exceeding 10% of the MRL. Dry weather and absence of children in the household were found to be associated with higher exposures in personal or indoor exposures. Given the small sample size, it is possible that these factors were confounded with unidentified household characteristics or activities that were the true determinants of exposure.

Adult↗

Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.

Potent non-peptidic alpha(v)beta(3) antagonists have been prepared where deletion of an amide bond from an earlier series of linear RGD-mimetics provides a novel series of chain-shortened alpha(v)beta(3) antagonists with significantly improved oral pharmacokinetics. These chain-shortened alpha(v)beta(3) antagonists represent structurally novel integrin inhibitors.

Administration, Oral↗

Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.

Potent non-peptidic alpha(v)beta(3) antagonists have been prepared incorporating various beta-amino acids as aspartic acid mimetics. Modification of the beta-alanine 3-substituents alters the potency and physicochemical properties of these receptor antagonists and in some cases provides orally bioavailable alpha(v)beta(3) inhibitors.

Amino Acids↗

Embryo research.

Explore the source record for details and available documents.

Advisory Committees↗